CAS 1000873-98-2

Tivantinib

Description:

Tivantinib, with the CAS number 1000873-98-2, is a small molecule inhibitor primarily known for its role in targeting the MET receptor tyrosine kinase. It is characterized by its ability to interfere with the signaling pathways associated with cell proliferation and survival, making it a subject of interest in cancer research, particularly for tumors that exhibit MET overexpression. Tivantinib is typically administered orally and has been investigated in clinical trials for various types of cancer, including non-small cell lung cancer and hepatocellular carcinoma. Its mechanism of action involves selective inhibition of MET, which can lead to reduced tumor growth and metastasis. The compound is often studied in combination with other therapeutic agents to enhance its efficacy. In terms of physical properties, Tivantinib is a crystalline solid with specific solubility characteristics that influence its bioavailability. As with many pharmaceutical compounds, its safety profile, potential side effects, and interactions with other drugs are critical considerations in its therapeutic application.

Formula: C₂₃H₁₉N₃O₂

InChI: InChI=1S/C23H19N3O2/c27-22-19(16-11-24-18-9-2-1-7-14(16)18)20(23(28)25-22)17-12-26-10-4-6-13-5-3-8-15(17)21(13)26/h1-3,5,7-9,11-12,19-20,24H,4,6,10H2,(H,25,27,28)/t19-,20-/m0/s1

InChI key: InChIKey=UCEQXRCJXIVODC-PMACEKPBSA-N

SMILES: O=C1[C@@H](C=2C=3C=4N(C2)CCCC4C=CC3)[C@@H](C(=O)N1)C=5C=6C(NC5)=CC=CC6

Synonyms:

• (3R,4R)-3-(5,6-Dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione
• ARQ 197
• 2,5-Pyrrolidinedione, 3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)-, (3R,4R)-
• (3R,4R)-3-(5,6-Dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)-2,5-pyrrolidinedione
• Tivantinib

Tivantinib

CAS: 1000873-98-2

Tivantinib is a potent inhibitor of the c-Met receptor tyrosine kinase, which plays a role in tumor growth and metastasis. This Chinese medicinal compound has been shown to have anticancer properties by inducing apoptosis in cancer cells and inhibiting cell cycle progression. Tivantinib has been found to be effective against a range of cancers, including leukemia and human solid tumors. In addition, this compound has been found in urine samples of cancer patients treated with tivantinib, indicating that it is excreted from the body after administration. Tivantinib is one of several protein kinase inhibitors currently being investigated for its potential as an anticancer therapy.

Formula: C₂₃H₁₉N₃O₂

Purity: Min. 95%

Molecular weight: 369.4 g/mol

Ref: 3D-AQB87398